New lung mass in a patient with granulomatosis with polyangiitis.
Carcinogenesis
Granulomatosis with polyangiitis
Lung neoplasm
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
09
04
2020
accepted:
03
07
2020
pubmed:
17
7
2020
medline:
16
11
2021
entrez:
17
7
2020
Statut:
ppublish
Résumé
Granulomatosis with polyangiitis (GPA) is a potentially lethal ANCA-associated small-vessel vasculitis characterized by a typical triad of upper respiratory tract, lung, and kidney involvement. Lung involvement in GPA occurs in 25-80% of cases. The most common radiographic and computed tomography (CT) abnormalities of pulmonary GPA are lung nodules and masses, very often multiple and with cavitation. As there are various clinical presentations, the diagnosis of GPA can be challenging, and the illness is difficult to distinguish from other diseases such as infection or malignancy. Following the improved survival rates in patients with GPA, there is accumulating evidence to suggest an increased occurrence of different types of cancer. Exposure to cyclophosphamide seems to be one of its main causes. We present the case of a patient with chronic GPA who was hospitalized owing to a new infiltrate in the lung, suggesting relapse of the disease, and finally diagnosed with small cell lung cancer. Data regarding lung cancer in GPA patients are limited. While there are some case reports and short case series in the literature, there are no detailed data regarding an association between CYC exposure and lung cancer development in vasculitis. It is necessary to consider the causes of pulmonary masses other than a GPA relapse. Bronchoscopy with biopsy and histopathological examination are crucial in proper differential diagnosis. GPA patients require long-term follow-up to monitor for the development of complications during treatment.
Identifiants
pubmed: 32671469
doi: 10.1007/s00296-020-04646-w
pii: 10.1007/s00296-020-04646-w
pmc: PMC7835303
doi:
Substances chimiques
Immunosuppressive Agents
0
Cyclophosphamide
8N3DW7272P
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
493-499Références
Cytokine. 2015 Feb;71(2):261-7
pubmed: 25461407
Clin Case Rep. 2017 Jul 05;5(8):1339-1340
pubmed: 28781854
Ann Intern Med. 1996 Mar 1;124(5):477-84
pubmed: 8602705
Best Pract Res Clin Rheumatol. 2020 Feb;34(1):101472
pubmed: 32029389
Intern Med. 2019 Nov 15;58(22):3299-3304
pubmed: 31327832
Arthritis Rheum. 2012 Feb;64(2):542-8
pubmed: 21953279
Int J Nephrol. 2017;2017:6013038
pubmed: 29403663
J Am Soc Nephrol. 1998 May;9(5):842-52
pubmed: 9596082
Autoimmun Rev. 2018 Jul;17(7):653-659
pubmed: 29730524
Arthritis Res Ther. 2018 Dec 6;20(1):270
pubmed: 30522515
Clin Nephrol. 1993 Jul;40(1):22-5
pubmed: 8358871
Sarcoidosis Vasc Diffuse Lung Dis. 2020;36(3):243-250
pubmed: 32476959
Eur Respir J. 2011 Feb;37(2):463-5
pubmed: 21282811
N Engl J Med. 2003 Jul 3;349(1):36-44
pubmed: 12840090
Arthritis Rheum. 2013 Jul;65(7):1913-21
pubmed: 23576072
Chest. 2013 May;143(5 Suppl):e1S-e29S
pubmed: 23649439
Ann Rheum Dis. 2011 Aug;70(8):1415-21
pubmed: 21616914
Kidney Int Rep. 2017 Nov 14;3(2):394-402
pubmed: 29725643
BJR Case Rep. 2020 Sep 29;6(2):20190114
pubmed: 33029377
Pneumonol Alergol Pol. 2009;77(5):469-73
pubmed: 19890827
Chest. 2018 Jun;153(6):1443-1465
pubmed: 29518379
Ann Rheum Dis. 2006 Jun;65(6):796-803
pubmed: 16284097
Nephrol Dial Transplant. 2010 Jul;25(7):2209-17
pubmed: 20100727
J Clin Rheumatol. 2018 Oct;24(7):361-367
pubmed: 29667942
Biomed Rep. 2016 Oct;5(4):511-513
pubmed: 27699023
J Rheumatol. 2008 Jan;35(1):100-5
pubmed: 17937462
Am J Hum Genet. 2007 May;80(5):867-75
pubmed: 17436241
Medicine (Baltimore). 2016 May;95(18):e3540
pubmed: 27149461
Ir J Med Sci. 2017 Feb;186(1):57-62
pubmed: 27156054
Arthritis Rheumatol. 2015 Dec;67(12):3270-8
pubmed: 26246307
Adv Exp Med Biol. 2013;788:349-53
pubmed: 23835997
Lupus. 2006;15(11):737-45
pubmed: 17153844
Arthritis Rheumatol. 2015 Jun;67(6):1629-36
pubmed: 25776953
Int J Cancer. 2002 Jul 1;100(1):82-5
pubmed: 12115591
Immunology. 2006 Oct;119(2):254-64
pubmed: 17005005
Clin Rheumatol. 2020 Sep;39(9):2501-2513
pubmed: 32219621
Clin Nephrol. 2014 Feb;81(2):132-7
pubmed: 22948118
Arthritis Rheum. 2007 Dec 15;57(8):1473-80
pubmed: 18050165
Reumatologia. 2015;53(5):286-91
pubmed: 27407261
Dis Markers. 2016;2016:2138627
pubmed: 27445423
Respirol Case Rep. 2017 Dec 22;6(2):e00284
pubmed: 29321928
Nefrologia. 2008;28(2):232
pubmed: 18454725
N Engl J Med. 2010 Jul 15;363(3):211-20
pubmed: 20647198
Anticancer Res. 2012 Apr;32(4):1119-36
pubmed: 22493341
Rev Port Pneumol. 2013 Jan-Feb;19(1):45-8
pubmed: 22748944
Ann Rheum Dis. 2004 Oct;63(10):1307-11
pubmed: 15130900
Rheumatology (Oxford). 2004 Dec;43(12):1532-5
pubmed: 15316126
Contemp Oncol (Pozn). 2016;20(3):215-9
pubmed: 27647985
PLoS One. 2015 May 14;10(5):e0126016
pubmed: 25973882
Ann Rheum Dis. 2011 Mar;70(3):488-94
pubmed: 21109517
Arthritis Rheum. 1999 Apr;42(4):751-6
pubmed: 10211890
Nihon Kokyuki Gakkai Zasshi. 2006 Feb;44(2):139-43
pubmed: 17228809
Eur J Cancer Prev. 2018 Sep;27(5):502-506
pubmed: 28379883
Best Pract Res Clin Rheumatol. 2013 Feb;27(1):45-56
pubmed: 23507056
Rheumatology (Oxford). 2015 Aug;54(8):1345-50
pubmed: 25234661
Kidney Int Rep. 2018 Nov 10;4(3):484-486
pubmed: 30899875
Cancer Chemother Pharmacol. 2016 Oct;78(4):661-71
pubmed: 27646791
J Rheumatol. 2017 Oct;44(10):1458-1467
pubmed: 28765242